Immunotherapy-Chemo combo targets tough neuroendocrine cancers
NCT ID NCT03582475
First seen Nov 12, 2025 · Last updated Jun 20, 2026 · Updated 24 times
Summary
This early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spread. Researchers are looking at how many patients respond and for how long, as well as safety. The goal is to see if this combination is worth testing in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV BLADDER CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (immunotherapy) plus platinum-based chemotherapy (cisplatin or carboplatin with etoposide or docetaxel)
What this could lead to
If this combination works, it could point toward a new treatment option for rare and aggressive neuroendocrine cancers of the bladder or prostate.
What could go wrong
This is a very early (Phase 1) and small (15 people) trial, so results may not apply to larger groups. The combination may cause significant side effects from both immunotherapy and chemotherapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.